Molecular Express, founded in April 1996, has made significant strides in biotechnology and vaccine development over the past decades. Early successes include the filing of a patent for vaccine technology in 1999 and several Phase I Small Business Innovation Research (SBIR) grants awarded for developing vaccines against influenza, HIV, and HSV-2 (Herpes Simplex Virus Type 2). In 2000, the company received a California Technology Investment Partnership (CalTIP) award as one of California's most innovative technology companies.
Throughout the 2000s, Molecular Express continued to expand its research and industry presence. Notably, in 2001, they presented groundbreaking findings on HSV-2 vaccine efficacy at prominent conferences and secured collaboration grants for anticancer and vaccine development. By 2007, Molecular Express had engaged in research funded by the National Institutes of Health (NIH) and National Cancer Institute (NCI) to advance vaccines and therapeutic manufacturing techniques.
Molecular Express remains dedicated to expanding its lab facilities and enhancing its role in biotechnology, continuing to innovate in cancer and infectious disease research.